Journal article
Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia: The LAPLACE-2 Randomized Clinical Trial
Abstract
IMPORTANCE: In phase 2 studies, evolocumab, a fully human monoclonal antibody to PCSK9, reduced LDL-C levels in patients receiving statin therapy.
OBJECTIVE: To evaluate the efficacy and tolerability of evolocumab when used in combination with a moderate- vs high-intensity statin.
Authors
Robinson JG; Nedergaard BS; Rogers WJ; Fialkow J; Neutel JM; Ramstad D; Somaratne R; Legg JC; Nelson P; Scott R
Journal
JAMA, Vol. 311, No. 18, pp. 1870–1883
Publisher
American Medical Association (AMA)
Publication Date
May 14, 2014
DOI
10.1001/jama.2014.4030
ISSN
0098-7484
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAnticholesteremic AgentsAtorvastatinAzetidinesDouble-Blind MethodDrug Therapy, CombinationDyslipidemiasEzetimibeFemaleFluorobenzenesHeptanoic AcidsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypercholesterolemiaMaleMiddle AgedPyrimidinesPyrrolesRosuvastatin CalciumSimvastatinSulfonamidesTreatment Outcome